-
1
-
-
58149398623
-
Translation of the Philadelphia chromosome into therapy for CML
-
Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
-
(2008)
Blood
, vol.112
, pp. 4808-4817
-
-
Druker, B.J.1
-
2
-
-
68549125412
-
Chronic myelogenous leukemia, BCR-ABL1+
-
Vardiman J.W. Chronic myelogenous leukemia, BCR-ABL1+. Am J Clin Pathol 2009, 132:250-260.
-
(2009)
Am J Clin Pathol
, vol.132
, pp. 250-260
-
-
Vardiman, J.W.1
-
3
-
-
34249074686
-
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial
-
Kantarjian H., Pasquini R., Hamerschlak N., Rousselot P., Holowiecki J., Jootar S., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007, 109:5143-5150.
-
(2007)
Blood
, vol.109
, pp. 5143-5150
-
-
Kantarjian, H.1
Pasquini, R.2
Hamerschlak, N.3
Rousselot, P.4
Holowiecki, J.5
Jootar, S.6
-
4
-
-
77953725855
-
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
-
Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
-
(2010)
N Engl J Med
, vol.362
, pp. 2260-2270
-
-
Kantarjian, H.1
Shah, N.P.2
Hochhaus, A.3
Cortes, J.4
Shah, S.5
Ayala, M.6
-
5
-
-
36348968931
-
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
-
Kantarjian H.M., Giles F., Gattermann N., Bhalla K., Alimena G., Palandri F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110:3540-3546.
-
(2007)
Blood
, vol.110
, pp. 3540-3546
-
-
Kantarjian, H.M.1
Giles, F.2
Gattermann, N.3
Bhalla, K.4
Alimena, G.5
Palandri, F.6
-
6
-
-
10744233716
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
-
O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
-
(2003)
N Engl J Med
, vol.348
, pp. 994-1004
-
-
O'Brien, S.G.1
Guilhot, F.2
Larson, R.A.3
Gathmann, I.4
Baccarani, M.5
Cervantes, F.6
-
7
-
-
77953691179
-
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
-
Saglio G., Kim D.-W., Issaragrisil S., Coutre P.l., Etienne G., Lobo C., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
-
(2010)
N Engl J Med
, vol.362
, pp. 2251-2259
-
-
Saglio, G.1
Kim, D.-W.2
Issaragrisil, S.3
Coutre, P.4
Etienne, G.5
Lobo, C.6
-
8
-
-
84859861616
-
The ongoing evolution of clinical endpoints in oncology
-
McCain J.A. The ongoing evolution of clinical endpoints in oncology. Manag Care 2010, 19:1-11.
-
(2010)
Manag Care
, vol.19
, pp. 1-11
-
-
McCain, J.A.1
-
9
-
-
84859813262
-
-
Food and Drug Administration. Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics. Available at: [accessed 26.06.11].
-
Food and Drug Administration. Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics, 2007. Available at: [accessed 26.06.11]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf.
-
(2007)
-
-
-
10
-
-
71849109054
-
Response definitions and European LeukemiaNet Management recommendations
-
Baccarani M., Castagnetti F., Gugliotta G., Palandri F., Soverini S. Response definitions and European LeukemiaNet Management recommendations. Best Pract Res Clin Haematol 2009, 22:331-341.
-
(2009)
Best Pract Res Clin Haematol
, vol.22
, pp. 331-341
-
-
Baccarani, M.1
Castagnetti, F.2
Gugliotta, G.3
Palandri, F.4
Soverini, S.5
-
11
-
-
84859862016
-
-
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Chronic Myelogenous Leukemia (Version 2.2012). © National Comprehensive Cancer Network, Inc. Available at: NCCN.org.
-
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Chronic Myelogenous Leukemia (Version 2.2012). © 2012 National Comprehensive Cancer Network, Inc. Available at: NCCN.org.
-
(2012)
-
-
-
12
-
-
70350717760
-
How I monitor residual disease in chronic myeloid leukemia
-
Radich J.P. How I monitor residual disease in chronic myeloid leukemia. Blood 2009, 114:3376-3381.
-
(2009)
Blood
, vol.114
, pp. 3376-3381
-
-
Radich, J.P.1
-
13
-
-
41449106741
-
Monitoring treatment of chronic myeloid leukemia
-
Baccarani M., Pane F., Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica 2008, 93:161-169.
-
(2008)
Haematologica
, vol.93
, pp. 161-169
-
-
Baccarani, M.1
Pane, F.2
Saglio, G.3
-
14
-
-
67749122513
-
Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia
-
Foroni L., Gerrard G., Nna E., Khorashad J.S., Stevens D., Swale B., et al. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia. American Journal of Hematology 2009, 84:517-522.
-
(2009)
American Journal of Hematology
, vol.84
, pp. 517-522
-
-
Foroni, L.1
Gerrard, G.2
Nna, E.3
Khorashad, J.S.4
Stevens, D.5
Swale, B.6
-
15
-
-
73349122639
-
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
-
Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
-
(2009)
J Clin Oncol
, vol.27
, pp. 6041-6051
-
-
Baccarani, M.1
Cortes, J.2
Pane, F.3
Niederwieser, D.4
Saglio, G.5
Apperley, J.6
-
16
-
-
10744229080
-
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
-
Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
-
(2003)
N Engl J Med
, vol.349
, pp. 1423-1432
-
-
Hughes, T.P.1
Kaeda, J.2
Branford, S.3
Rudzki, Z.4
Hochhaus, A.5
Hensley, M.L.6
-
17
-
-
33745603988
-
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
-
Hughes T.P., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
-
(2006)
Blood
, vol.108
, pp. 28-37
-
-
Hughes, T.P.1
Deininger, M.2
Hochhaus, A.3
Branford, S.4
Radich, J.5
Kaeda, J.6
-
18
-
-
0027164941
-
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group
-
Hehlmann R., Heimpel H., Hasford J., Kolb H.J., Pralle H., Hossfeld D.K., et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993, 82:398-407.
-
(1993)
Blood
, vol.82
, pp. 398-407
-
-
Hehlmann, R.1
Heimpel, H.2
Hasford, J.3
Kolb, H.J.4
Pralle, H.5
Hossfeld, D.K.6
-
19
-
-
23444462074
-
Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia
-
Italian Cooperative Study Group on Chronic Myeloid Leukemia
-
Italian Cooperative Study Group on Chronic Myeloid Leukemia Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med 1994, 330:820-825.
-
(1994)
N Engl J Med
, vol.330
, pp. 820-825
-
-
-
20
-
-
0029154919
-
A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase
-
Ohnishi K., Ohno R., Tomonaga M., Kamada N., Onozawa K., Kuramoto A., et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995, 86:906-916.
-
(1995)
Blood
, vol.86
, pp. 906-916
-
-
Ohnishi, K.1
Ohno, R.2
Tomonaga, M.3
Kamada, N.4
Onozawa, K.5
Kuramoto, A.6
-
21
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
-
(2006)
N Engl J Med
, vol.355
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
Gathmann, I.4
Kantarjian, H.5
Gattermann, N.6
-
22
-
-
75749105885
-
Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study
-
Cortes J.E., Baccarani M., Guilhot F., Druker B.J., Branford S., Kim D.W., et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010, 28:424-430.
-
(2010)
J Clin Oncol
, vol.28
, pp. 424-430
-
-
Cortes, J.E.1
Baccarani, M.2
Guilhot, F.3
Druker, B.J.4
Branford, S.5
Kim, D.W.6
-
23
-
-
21144451094
-
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
-
O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500-4505.
-
(2005)
Cancer Res
, vol.65
, pp. 4500-4505
-
-
O'Hare, T.1
Walters, D.K.2
Stoffregen, E.P.3
Jia, T.4
Manley, P.W.5
Mestan, J.6
-
24
-
-
13844251975
-
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
-
Weisberg E., Manley P.W., Breitenstein W., Bruggen J., Cowan-Jacob S.W., Ray A., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-141.
-
(2005)
Cancer Cell
, vol.7
, pp. 129-141
-
-
Weisberg, E.1
Manley, P.W.2
Breitenstein, W.3
Bruggen, J.4
Cowan-Jacob, S.W.5
Ray, A.6
-
25
-
-
79251546724
-
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
-
Kantarjian H.M., Giles F.J., Bhalla K.N., Pinilla-Ibarz J., Larson R.A., Gattermann N., et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011, 117:1141-1145.
-
(2011)
Blood
, vol.117
, pp. 1141-1145
-
-
Kantarjian, H.M.1
Giles, F.J.2
Bhalla, K.N.3
Pinilla-Ibarz, J.4
Larson, R.A.5
Gattermann, N.6
-
26
-
-
83855164150
-
Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase
-
Nicolini F.E., Turkina A., Shen Z.X., Gallagher N., Jootar S., Powell B.L., et al. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Cancer 2011, 118:118-126.
-
(2011)
Cancer
, vol.118
, pp. 118-126
-
-
Nicolini, F.E.1
Turkina, A.2
Shen, Z.X.3
Gallagher, N.4
Jootar, S.5
Powell, B.L.6
-
27
-
-
70349306853
-
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value
-
Hochhaus A., Muller M.C., Radich J., Branford S., Kantarjian H.M., Hanfstein B., et al. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 2009, 23:1628-1633.
-
(2009)
Leukemia
, vol.23
, pp. 1628-1633
-
-
Hochhaus, A.1
Muller, M.C.2
Radich, J.3
Branford, S.4
Kantarjian, H.M.5
Hanfstein, B.6
-
28
-
-
70149105272
-
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)
-
Kantarjian H., Pasquini R., Levy V., Jootar S., Holowiecki J., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009, 115:4136-4147.
-
(2009)
Cancer
, vol.115
, pp. 4136-4147
-
-
Kantarjian, H.1
Pasquini, R.2
Levy, V.3
Jootar, S.4
Holowiecki, J.5
Hamerschlak, N.6
-
29
-
-
80055070888
-
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib
-
Cortes J.E., Kantarjian H.M., Brummendorf T.H., Kim D.W., Turkina A.G., Shen Z.X., et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib. Blood 2011, 118:4567-4576.
-
(2011)
Blood
, vol.118
, pp. 4567-4576
-
-
Cortes, J.E.1
Kantarjian, H.M.2
Brummendorf, T.H.3
Kim, D.W.4
Turkina, A.G.5
Shen, Z.X.6
-
30
-
-
73949145209
-
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia
-
Rosti G., Palandri F., Castagnetti F., Breccia M., Levato L., Gugliotta G., et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009, 114:4933-4938.
-
(2009)
Blood
, vol.114
, pp. 4933-4938
-
-
Rosti, G.1
Palandri, F.2
Castagnetti, F.3
Breccia, M.4
Levato, L.5
Gugliotta, G.6
-
31
-
-
75749090051
-
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase
-
Cortes J.E., Jones D., O'Brien S., Jabbour E., Konopleva M., Ferrajoli A., et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010, 28:392-397.
-
(2010)
J Clin Oncol
, vol.28
, pp. 392-397
-
-
Cortes, J.E.1
Jones, D.2
O'Brien, S.3
Jabbour, E.4
Konopleva, M.5
Ferrajoli, A.6
-
32
-
-
79952903358
-
Nilotinib 300mg twice daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: updated results of the ICORG 0802 phase 2 study with analysis of the GeneXpert system versus IS BCR-ABL RQ PCR
-
(ASH Annual Meeting Abstracts)
-
Conneally E., Swords R.T., Giles F.J., McMullin M.F., Coutre P.l., Langabeer S., et al. Nilotinib 300mg twice daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: updated results of the ICORG 0802 phase 2 study with analysis of the GeneXpert system versus IS BCR-ABL RQ PCR. Blood 2010, 116:3427. (ASH Annual Meeting Abstracts).
-
(2010)
Blood
, vol.116
, pp. 3427
-
-
Conneally, E.1
Swords, R.T.2
Giles, F.J.3
McMullin, M.F.4
Coutre, P.5
Langabeer, S.6
-
33
-
-
80052383499
-
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
-
Kantarjian H.M., Hochhaus A., Saglio G., De Souza Santos F.P., Flinn I.W., Stenke L., et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011, 12:841-851.
-
(2011)
Lancet Oncol
, vol.12
, pp. 841-851
-
-
Kantarjian, H.M.1
Hochhaus, A.2
Saglio, G.3
De Souza Santos, F.P.4
Flinn, I.W.5
Stenke, L.6
-
34
-
-
75749129911
-
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia
-
Cortes J.E., Jones D., O'Brien S., Jabbour E., Ravandi F., Koller C., et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010, 28:398-404.
-
(2010)
J Clin Oncol
, vol.28
, pp. 398-404
-
-
Cortes, J.E.1
Jones, D.2
O'Brien, S.3
Jabbour, E.4
Ravandi, F.5
Koller, C.6
-
35
-
-
79952787880
-
A randomized phase II trial of dasatinib 100mg vs imatinib 400mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 intergroup trial
-
LBA-6 (ASH Annual Meeting Abstracts)
-
Radich J.P., Kopecky K.J., Kamel-Reid S., Stock W., Paietta E., Wadleigh M., et al. A randomized phase II trial of dasatinib 100mg vs imatinib 400mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 intergroup trial. Blood 2010, 116. LBA-6 (ASH Annual Meeting Abstracts).
-
(2010)
Blood
, vol.116
-
-
Radich, J.P.1
Kopecky, K.J.2
Kamel-Reid, S.3
Stock, W.4
Paietta, E.5
Wadleigh, M.6
-
36
-
-
79952038795
-
Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up
-
(ASH Annual Meeting Abstracts)
-
Shah N., Kantarjian H., Hochhaus A., Cortes J.E., Bradley-Garelik M.B., Zhu C., et al. Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up. Blood 2010, 116:206. (ASH Annual Meeting Abstracts).
-
(2010)
Blood
, vol.116
, pp. 206
-
-
Shah, N.1
Kantarjian, H.2
Hochhaus, A.3
Cortes, J.E.4
Bradley-Garelik, M.B.5
Zhu, C.6
-
37
-
-
78650218988
-
An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia
-
(ASH Annual Meeting Abstracts)
-
Gambacorti-Passerini C., Kim D.-W., Kantarjian H.M., Brummendorf T.H., Dyagil I., Griskevicius L., et al. An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Blood 2010, 116:208. (ASH Annual Meeting Abstracts).
-
(2010)
Blood
, vol.116
, pp. 208
-
-
Gambacorti-Passerini, C.1
Kim, D.-W.2
Kantarjian, H.M.3
Brummendorf, T.H.4
Dyagil, I.5
Griskevicius, L.6
-
38
-
-
83755180770
-
Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up
-
Gambacorti-Passerini C., Cortes J.E., Kim D., Kantarjian H., Khattry N., Lipton J.H., et al. Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up. ASCO Meeting Abstracts 2011, 29:6509.
-
(2011)
ASCO Meeting Abstracts
, vol.29
, pp. 6509
-
-
Gambacorti-Passerini, C.1
Cortes, J.E.2
Kim, D.3
Kantarjian, H.4
Khattry, N.5
Lipton, J.H.6
-
39
-
-
79952038063
-
ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)
-
(ASH Annual Meeting Abstracts)
-
Hughes T.P., Hochhaus A., Saglio G., Kim D.-W., Jootar S., Coutre P.l., et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Blood 2010, 116:207. (ASH Annual Meeting Abstracts).
-
(2010)
Blood
, vol.116
, pp. 207
-
-
Hughes, T.P.1
Hochhaus, A.2
Saglio, G.3
Kim, D.-W.4
Jootar, S.5
Coutre, P.6
-
40
-
-
83655174011
-
Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): two-year follow-up from DASISION
-
Kantarjian H., Shah N.P., Cortes J.E., Baccarani M., Bradley-Garelik M.B., Zhu C., et al. Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): two-year follow-up from DASISION. ASCO Meeting Abstracts 2011, 29:6510.
-
(2011)
ASCO Meeting Abstracts
, vol.29
, pp. 6510
-
-
Kantarjian, H.1
Shah, N.P.2
Cortes, J.E.3
Baccarani, M.4
Bradley-Garelik, M.B.5
Zhu, C.6
-
41
-
-
0037441629
-
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis
-
Kantarjian H.M., O'Brien S., Cortes J.E., Shan J., Giles F.J., Rios M.B., et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003, 97:1033-1041.
-
(2003)
Cancer
, vol.97
, pp. 1033-1041
-
-
Kantarjian, H.M.1
O'Brien, S.2
Cortes, J.E.3
Shan, J.4
Giles, F.J.5
Rios, M.B.6
-
42
-
-
77949767505
-
International randomized study of interferon versus STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib
-
(ASH Annual Meeting Abstracts)
-
Deininger M., O'Brien S.G., Guilhot F., Goldman J.M., Hochhaus A., Hughes T.P., et al. International randomized study of interferon versus STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009, 114:1126. (ASH Annual Meeting Abstracts).
-
(2009)
Blood
, vol.114
, pp. 1126
-
-
Deininger, M.1
O'Brien, S.G.2
Guilhot, F.3
Goldman, J.M.4
Hochhaus, A.5
Hughes, T.P.6
-
43
-
-
77958595179
-
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS)
-
Hughes T.P., Hochhaus A., Branford S., Muller M.C., Kaeda J.S., Foroni L., et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS). Blood 2010, 116:3758-3765.
-
(2010)
Blood
, vol.116
, pp. 3758-3765
-
-
Hughes, T.P.1
Hochhaus, A.2
Branford, S.3
Muller, M.C.4
Kaeda, J.S.5
Foroni, L.6
-
44
-
-
79955018499
-
Tolerability-adapted imatinib 800mg/d versus 400mg/d versus 400mg/d plus interferon-{alpha} in newly diagnosed chronic myeloid leukemia
-
Hehlmann R., Lauseker M., Jung-Munkwitz S., Leitner A., Muller M.C., Pletsch N., et al. Tolerability-adapted imatinib 800mg/d versus 400mg/d versus 400mg/d plus interferon-{alpha} in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011, 29:1634-1642.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1634-1642
-
-
Hehlmann, R.1
Lauseker, M.2
Jung-Munkwitz, S.3
Leitner, A.4
Muller, M.C.5
Pletsch, N.6
-
45
-
-
79952327332
-
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy
-
Hanfstein B., Muller M.C., Kreil S., Ernst T., Schenk T., Lorentz C., et al. Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica 2011, 96:360-366.
-
(2011)
Haematologica
, vol.96
, pp. 360-366
-
-
Hanfstein, B.1
Muller, M.C.2
Kreil, S.3
Ernst, T.4
Schenk, T.5
Lorentz, C.6
-
46
-
-
77958577395
-
Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter?
-
Kim D.H., Sriharsha L., Jung C.W., Kamel-Reid S., Radich J.P., Lipton J.H. Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter?. Am J Hematol 2010, 85:856-862.
-
(2010)
Am J Hematol
, vol.85
, pp. 856-862
-
-
Kim, D.H.1
Sriharsha, L.2
Jung, C.W.3
Kamel-Reid, S.4
Radich, J.P.5
Lipton, J.H.6
-
47
-
-
84859862018
-
Kinetics of molecular response with different tyrosine kinase inhibitors (TKI) used as frontline therapy in chronic myeloid leukemia-chronic phase (CML CP)
-
(ASH Annual Meeting Abstracts)
-
Naqvi K., Kantarjian H.M., Luthra R., Jabbour E., O'Brien S., Burton E.M., et al. Kinetics of molecular response with different tyrosine kinase inhibitors (TKI) used as frontline therapy in chronic myeloid leukemia-chronic phase (CML CP). Blood 2011, 118:3784. (ASH Annual Meeting Abstracts).
-
(2011)
Blood
, vol.118
, pp. 3784
-
-
Naqvi, K.1
Kantarjian, H.M.2
Luthra, R.3
Jabbour, E.4
O'Brien, S.5
Burton, E.M.6
-
48
-
-
84859857734
-
Dasatinib and imatinib-induced reductions in BCR-ABL transcript levels below 10% at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of molecular response kinetics in the DASISION trial
-
(ASH Annual Meeting Abstracts)
-
Hochhaus A., Saglio G., Chuah C., Pavlovsky C., Garelick M.B.B., Lambert A., et al. Dasatinib and imatinib-induced reductions in BCR-ABL transcript levels below 10% at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of molecular response kinetics in the DASISION trial. Blood 2011, 118:2767. (ASH Annual Meeting Abstracts).
-
(2011)
Blood
, vol.118
, pp. 2767
-
-
Hochhaus, A.1
Saglio, G.2
Chuah, C.3
Pavlovsky, C.4
Garelick, M.B.B.5
Lambert, A.6
-
49
-
-
84864233871
-
Molecular and cytogenetic response after 3months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients-a follow-up analysis of the German CML Study IV
-
(ASH Annual Meeting Abstracts)
-
Hanfstein B., Muller M.C., Erben P., Lauseker M., Saussele S., Proetel U., et al. Molecular and cytogenetic response after 3months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients-a follow-up analysis of the German CML Study IV. Blood 2011, 118:783. (ASH Annual Meeting Abstracts).
-
(2011)
Blood
, vol.118
, pp. 783
-
-
Hanfstein, B.1
Muller, M.C.2
Erben, P.3
Lauseker, M.4
Saussele, S.5
Proetel, U.6
-
50
-
-
78049528573
-
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
-
Mahon F.X., Rea D., Guilhot J., Guilhot F., Huguet F., Nicolini F., et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010, 11:1029-1035.
-
(2010)
Lancet Oncol
, vol.11
, pp. 1029-1035
-
-
Mahon, F.X.1
Rea, D.2
Guilhot, J.3
Guilhot, F.4
Huguet, F.5
Nicolini, F.6
-
51
-
-
84859827027
-
Cessation of dasatinib or nilotinib therapy in chronic-phase chronic myeloid leukaemia patients with sustained complete molecular responses
-
Abstract 1014
-
Rea D., Rousselot P., Nicolini F., Legros L., Tulliez M., Guilhot F., et al. Cessation of dasatinib or nilotinib therapy in chronic-phase chronic myeloid leukaemia patients with sustained complete molecular responses. 16th Congress of the European Hematology Association (EHA) 2011, Abstract 1014.
-
(2011)
16th Congress of the European Hematology Association (EHA)
-
-
Rea, D.1
Rousselot, P.2
Nicolini, F.3
Legros, L.4
Tulliez, M.5
Guilhot, F.6
-
52
-
-
80355125811
-
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features
-
Ross D.M., Bartley P.A., Goyne J., Morley A.A., Seymour J.F., Grigg A.P. Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features. Haematologica 2011, 96:1720-1722.
-
(2011)
Haematologica
, vol.96
, pp. 1720-1722
-
-
Ross, D.M.1
Bartley, P.A.2
Goyne, J.3
Morley, A.A.4
Seymour, J.F.5
Grigg, A.P.6
-
53
-
-
67049087117
-
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
-
Noens L., van Lierde M.A., De Bock R., Verhoef G., Zachee P., Berneman Z., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
-
(2009)
Blood
, vol.113
, pp. 5401-5411
-
-
Noens, L.1
van Lierde, M.A.2
De Bock, R.3
Verhoef, G.4
Zachee, P.5
Berneman, Z.6
-
54
-
-
77952467377
-
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
-
Marin D., Bazeos A., Mahon F.X., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28:2381-2388.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2381-2388
-
-
Marin, D.1
Bazeos, A.2
Mahon, F.X.3
Eliasson, L.4
Milojkovic, D.5
Bua, M.6
-
55
-
-
79953823237
-
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
-
Ibrahim A.R., Eliasson L., Apperley J.F., Milojkovic D., Bua M., Szydlo R., et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011, 117:3733-3736.
-
(2011)
Blood
, vol.117
, pp. 3733-3736
-
-
Ibrahim, A.R.1
Eliasson, L.2
Apperley, J.F.3
Milojkovic, D.4
Bua, M.5
Szydlo, R.6
-
56
-
-
0033520092
-
Chronic myelogenous leukemia: biology and therapy
-
Faderl S., Talpaz M., Estrov Z., Kantarjian H.M. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999, 131:207-219.
-
(1999)
Ann Intern Med
, vol.131
, pp. 207-219
-
-
Faderl, S.1
Talpaz, M.2
Estrov, Z.3
Kantarjian, H.M.4
|